Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 101–110, page 11 of 20. Filter these by subject, year and score in the research library →
-
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort studyResearch summary
Research summaries · alzhub.org/study/dynamic-changes-in-plasma-biomarkers-of-alzheimer-s-disease-in-42785333
The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants …
-
Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisión de la literatura (2015-2025)Research summary
Research summaries · alzhub.org/study/eficacia-del-lecanemab-en-el-tratamiento-de-la-enfermedad-de-ee62b24d
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for …
-
Research summaries · alzhub.org/study/higher-phosphorylated-tau-levels-predict-cognitive-decline-and-41276859
Background Lecanemab was recently approved for the treatment of patients with early Alzheimer's disease (AD) and demonstrated reduced senile amyloid plaque and less decline on the measures of cognition and function in clinical …
-
Intracerebral hemorrhage following mild ARIA-H in an APOE ε2 carrier receiving lecanemabResearch summary
Research summaries · alzhub.org/study/intracerebral-hemorrhage-following-mild-aria-h-in-an-apoe-2-carrier-39702440
… (APOE)ε2 carrier receiving lecanemab who developed late onset intracerebral hemorrhage (ICH) following amyloid-related imaging abnormalities-hemorrhage (ARIA-H). Method We detail the history and neuroimaging findings of a …
-
Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemabResearch summary
Research summaries · alzhub.org/study/ischemic-stroke-associated-with-amyloid-related-imaging-abnormalities-39215494
Introduction Anti-amyloid antibody therapies such as lecanemab are increasingly being used to treat Alzheimer's disease (AD). These therapies are associated with a high rate of amyloid-related imaging abnormalities (ARIA). …
-
Lecanemab and Donanemab Combination Therapy for Alzheimer’s Disease-The Cocktail May Work Even Better TogetherResearch summary
Research summaries · alzhub.org/study/lecanemab-and-donanemab-combination-therapy-for-alzheimers-disease-41773886
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. They do not work on the same target, however. While Lecanemab targets pathologic amyloid protofibrils, …
-
Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopesResearch summary
Research summaries · alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407
Abstract Background Lecanemab, donanemab, and aducanumab all bind to aggregates of Aβ and all clear amyloid PET in clinical trials, but they are proposed to bind different forms of Aβ and cause amyloid related imaging abnormality …
-
Lecanemab-Associated Amyloid-β Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's DiseaseResearch summary
Research summaries · alzhub.org/study/lecanemab-associated-amyloid-protofibril-in-cerebrospinal-fluid-39761671
Objective The Clarity AD phase III trial showed that lecanemab reduced amyloid markers in early Alzheimer's disease (AD) and resulted in less decline on measures of cognition and function than placebo. Herein, we aimed to …
-
Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System databaseResearch summary
Research summaries · alzhub.org/study/post-marketing-safety-concerns-with-lecanemab-a-pharmacovigilance-39780222
Background The safety data of lecanemab in the post-marketing period has yet to be fully investigated in the current literature. We aimed to identify and characterise the safety profile of lecanemab in the post-marketing period. …
-
Research summaries · alzhub.org/study/real-world-effectiveness-of-monoclonal-antibody-lecanemab-versus-42332768
… disease (AD), whereas lecanemab may modify disease progression; however, real-world evidence on its safety and clinical impact remains limited. Therefore, this study aimed to compare the safety and effectiveness of initiating …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.